Literature DB >> 26348927

The Role of a National Biocontainment Laboratory in Emergencies.

James W Le Duc, Thomas G Ksiazek.   

Abstract

Over a decade ago, the National Institutes of Health awarded partial support for the construction and operation of 2 National Biocontainment Laboratories, with the condition that they would be available to assist in the event of public health emergencies-although how a biocontainment facility located on an academic campus might contribute was not defined. Here we offer examples of how one of these laboratories has contributed to a coordinated response to 2 recent international public health emergencies. Essential assets for success include highly trained and experienced staff, access to reference pathogens and reagents, cutting-edge knowledge of the field, appropriate biocontainment facilities, robust biosafety and biosecurity programs, and availability of modern instrumentation. The ability to marry the strengths of academia in basic and applied research with access to appropriate biocontainment facilities while drawing on a highly skilled cadre of experienced experts has proven extremely valuable in the response to recent national emergencies and will continue to do so in the future. Areas where additional planning and preparation are needed have also been identified through these experiences.

Mesh:

Year:  2015        PMID: 26348927      PMCID: PMC4582681          DOI: 10.1089/hs.2015.0023

Source DB:  PubMed          Journal:  Health Secur        ISSN: 2326-5094


  2 in total

1.  Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates.

Authors:  Emily P Thi; Chad E Mire; Amy C H Lee; Joan B Geisbert; Joy Z Zhou; Krystle N Agans; Nicholas M Snead; Daniel J Deer; Trisha R Barnard; Karla A Fenton; Ian MacLachlan; Thomas W Geisbert
Journal:  Nature       Date:  2015-04-22       Impact factor: 49.962

2.  Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.

Authors:  Chad E Mire; Demetrius Matassov; Joan B Geisbert; Theresa E Latham; Krystle N Agans; Rong Xu; Ayuko Ota-Setlik; Michael A Egan; Karla A Fenton; David K Clarke; John H Eldridge; Thomas W Geisbert
Journal:  Nature       Date:  2015-04-08       Impact factor: 49.962

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.